New drug TB-500 aims to improve blood vessel health in heart disease patients

NCT ID NCT07487363

Recruiting now Disease control Sponsor: Hudson Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an experimental drug called TB-500 in 80 adults with stable atherosclerotic cardiovascular disease. The main goal is to see if the drug is safe and tolerable. Researchers will also measure changes in blood vessel function and inflammation as early signs of potential benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TB-500 (a fragment of thymosin beta 4)
What this could lead to: If it works, this could point toward a new treatment to improve blood vessel function and reduce inflammation in people with stable heart disease.
What could go wrong: This is an early phase 1/2 trial with only 80 participants, so it is primarily testing safety. It may not show clear benefit, and the drug could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASES ENDOTHELIAL DYSFUNCTION

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.